NASDAQ:VIGL - Nasdaq - US92673K1088 - Common Stock - Currency: USD
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Mentions: HURA
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
/PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Vigil...
The consensus price target hints at an 86.7% upside potential for Vigil Neuroscience (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
U.S. stock futures were fluctuating on Friday after a mixed close on Thursday. Futures of benchmark indices were mixed in premarket.
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the
Vigil Neuroscience shares jumped nearly 250% Thursday after the Alzheimer's disease drug developer reached a deal to be acquired by French pharmaceutical giant Sanofi.
Amgen's weight loss candidate reported mixed phase 2 data, but the company has other weapons. Viking Therapeutics' leading anti-obesity program aced mid-stage studies, and it's not its only promising candidate. Deciding between these two stocks might come down to each investor's style, priorities, and risk tolerance.
SNY inks an agreement to acquire VIGL and its pipeline candidate VG-3927, which is being developed to treat Alzheimer's disease.
The company is working on an Alzheimer's treatment that increases the activity of TREM2, a neuroinflammation target.
Under the terms of the deal, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash at closing.
Apple Inc. (NASDAQ:AAPL) has authorized Fortnite’s re-entry into the US App Store, bringing an end to a five-year absence that started in 2020. The ruling comes after the court warned the firm on Monday to either allow the app or settle its conflict with Epic Games. Epic submitted Fortnite for assessment on May 9, but […]
On May 20, Australian billionaire Brett Blundy’s investment vehicle, BBRC International Private Limited, increased its stake in the lingerie manufacturer, Victoria’s Secret & Co. (NYSE:VSCO), to implement a limited-duration shareholder rights plan. According to Board Chair Donna James, the “poison pill” prevents anyone from taking over the business without paying all shareholders a fair premium. […]
Nippon Steel Corporation (OTC:NPSCY) of Japan is still determined to buy out United States Steel Corporation (NYSE:X) in its entirety, even in the face of regulatory scrutiny. The business’s plan was verified by Vice Chairman Takahiro Mori before the May 21 deadline for the CFIUS’s updated national security review, which is overseen by U.S. Treasury […]
Chevron Corporation (NYSE:CVX) has shown interest in tapping into Indonesia’s oil and gas assets with substantial reserves, according to Djoko Siswanto, head of the country’s upstream regulator SKK Migas, who made the statement on May 20. Djoko noted that Chevron is evaluating blocks that could hold approximately 15 trillion cubic feet of gas, though the […]